-
1
-
-
33645105318
-
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
-
PID: 16415119
-
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34(4):600–7
-
(2006)
Drug Metab Dispos.
, vol.34
, Issue.4
, pp. 600-607
-
-
Rehmel, J.L.1
Eckstein, J.A.2
Farid, N.A.3
Heim, J.B.4
Kasper, S.C.5
Kurihara, A.6
-
2
-
-
60649112469
-
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
-
PID: 19249633
-
Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31
-
(2009)
Lancet.
, vol.373
, Issue.9665
, pp. 723-731
-
-
Montalescot, G.1
Wiviott, S.D.2
Braunwald, E.3
Murphy, S.A.4
Gibson, C.M.5
McCabe, C.H.6
-
3
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
PID: 17982182
-
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15
-
(2007)
N Engl J Med.
, vol.357
, Issue.20
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
Montalescot, G.4
Ruzyllo, W.5
Gottlieb, S.6
-
4
-
-
37349111065
-
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
-
PID: 18056526
-
Wiviott SD, Trenk D, Frelinger AL, O’Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923–32
-
(2007)
Circulation.
, vol.116
, Issue.25
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
O’Donoghue, M.4
Neumann, F.J.5
Michelson, A.D.6
-
5
-
-
33644507056
-
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir
-
PID: 16513448
-
Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006;79(3):243–54
-
(2006)
Clin Pharmacol Ther.
, vol.79
, Issue.3
, pp. 243-254
-
-
Culm-Merdek, K.E.1
von Moltke, L.L.2
Gan, L.3
Horan, K.A.4
Reynolds, R.5
Harmatz, J.S.6
-
6
-
-
0034209862
-
Differential impairment of triazolam and zolpidem clearance by ritonavir
-
PID: 10935688
-
Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr. 2000;24(2):129–36
-
(2000)
J Acquir Immune Defic Syndr.
, vol.24
, Issue.2
, pp. 129-136
-
-
Greenblatt, D.J.1
von Moltke, L.L.2
Harmatz, J.S.3
Durol, A.L.4
Daily, J.P.5
Graf, J.A.6
-
7
-
-
33745433348
-
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers
-
PID: 16639344
-
Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42(1):52–60
-
(2006)
J Acquir Immune Defic Syndr.
, vol.42
, Issue.1
, pp. 52-60
-
-
Yeh, R.F.1
Gaver, V.E.2
Patterson, K.B.3
Rezk, N.L.4
Baxter-Meheux, F.5
Blake, M.J.6
-
8
-
-
84945909920
-
Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS
-
PID: 26566368
-
Putcharoen O, Do T, Avihingsanon A, Ruxrungtham K. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS. Drug Des Devel Ther. 2015;9:5763–9
-
(2015)
Drug Des Devel Ther.
, vol.9
, pp. 5763-5769
-
-
Putcharoen, O.1
Do, T.2
Avihingsanon, A.3
Ruxrungtham, K.4
-
9
-
-
79955432850
-
-
Gilead Sciences International Ltd, Accessed May 2017
-
Tybost: EU summary of product characteristics. Gilead Sciences International Ltd. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002572/WC500153014.pdf. Accessed May 2017
-
(2013)
Tybost: EU Summary of Product Characteristics
-
-
-
10
-
-
77956150896
-
Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer
-
PID: 24900196
-
Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1(5):209–13
-
(2010)
ACS Med Chem Lett.
, vol.1
, Issue.5
, pp. 209-213
-
-
Xu, L.1
Liu, H.2
Murray, B.P.3
Callebaut, C.4
Lee, M.S.5
Hong, A.6
-
11
-
-
55249096740
-
Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors
-
PID: 18845918
-
Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008;22(Suppl 3):S19–26
-
(2008)
AIDS.
, vol.22
, pp. S19-S26
-
-
Boccara, F.1
-
12
-
-
84873830235
-
HIV and coronary heart disease: time for a better understanding
-
PID: 23369416
-
Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61(5):511–23
-
(2013)
J Am Coll Cardiol.
, vol.61
, Issue.5
, pp. 511-523
-
-
Boccara, F.1
Lang, S.2
Meuleman, C.3
Ederhy, S.4
Mary-Krause, M.5
Costagliola, D.6
-
13
-
-
67651125105
-
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis
-
PID: 19390417
-
Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059–67
-
(2009)
AIDS.
, vol.23
, Issue.9
, pp. 1059-1067
-
-
Hsue, P.Y.1
Hunt, P.W.2
Schnell, A.3
Kalapus, S.C.4
Hoh, R.5
Ganz, P.6
-
14
-
-
0037463620
-
Acute myocardial infarction in human immunodeficiency virus-infected patients
-
PID: 12588205
-
Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med. 2003;163(4):457–60
-
(2003)
Arch Intern Med.
, vol.163
, Issue.4
, pp. 457-460
-
-
Matetzky, S.1
Domingo, M.2
Kar, S.3
Noc, M.4
Shah, P.K.5
Kaul, S.6
-
15
-
-
84929204828
-
Experimental design and analysis and their reporting: new guidance for publication in BJP
-
PID: 26114403
-
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al. Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol. 2015;172(14):3461–71
-
(2015)
Br J Pharmacol.
, vol.172
, Issue.14
, pp. 3461-3471
-
-
Curtis, M.J.1
Bond, R.A.2
Spina, D.3
Ahluwalia, A.4
Alexander, S.P.5
Giembycz, M.A.6
-
16
-
-
66149114859
-
Comparison of VerifyNow-P2Y12 test and flow cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?
-
PID: 19419580
-
Godino C, Mendolicchio L, Figini F, Latib A, Sharp AS, Cosgrave J, et al. Comparison of VerifyNow-P2Y12 test and flow cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J. 2009;7:4
-
(2009)
Thromb J.
, vol.7
, pp. 4
-
-
Godino, C.1
Mendolicchio, L.2
Figini, F.3
Latib, A.4
Sharp, A.S.5
Cosgrave, J.6
-
17
-
-
44949173754
-
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
-
PID: 18263931
-
Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992–1000
-
(2008)
Eur Heart J.
, vol.29
, Issue.8
, pp. 992-1000
-
-
Price, M.J.1
Endemann, S.2
Gollapudi, R.R.3
Valencia, R.4
Stinis, C.T.5
Levisay, J.P.6
-
18
-
-
59849120163
-
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up
-
PID: 19118249
-
Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237–42
-
(2009)
Circulation.
, vol.119
, Issue.2
, pp. 237-242
-
-
Marcucci, R.1
Gori, A.M.2
Paniccia, R.3
Giusti, B.4
Valente, S.5
Giglioli, C.6
-
19
-
-
77249098703
-
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting
-
PID: 20142119
-
Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis. 2010;103(1):39–45
-
(2010)
Arch Cardiovasc Dis.
, vol.103
, Issue.1
, pp. 39-45
-
-
Cuisset, T.1
Frere, C.2
Poyet, R.3
Quilici, J.4
Gaborit, B.5
Bali, L.6
-
20
-
-
84969731113
-
High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values
-
PID: 27236738
-
Leunissen TC, Peeters Weem SM, Urbanus RT, den Ruijter HM, Moll FL, Asselbergs FW, et al. High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values. Eur J Vasc Endovasc Surg. 2016;52(2):198–204
-
(2016)
Eur J Vasc Endovasc Surg.
, vol.52
, Issue.2
, pp. 198-204
-
-
Leunissen, T.C.1
Peeters Weem, S.M.2
Urbanus, R.T.3
den Ruijter, H.M.4
Moll, F.L.5
Asselbergs, F.W.6
-
21
-
-
80054966619
-
Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients
-
PID: 21550074
-
Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism. 2011;60(11):1584–9
-
(2011)
Metabolism.
, vol.60
, Issue.11
, pp. 1584-1589
-
-
Daali, Y.1
Ancrenaz, V.2
Bosilkovska, M.3
Dayer, P.4
Desmeules, J.5
-
22
-
-
84872151682
-
Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers
-
PID: 22900583
-
Ancrenaz V, Deglon J, Samer C, Staub C, Dayer P, Daali Y, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;112(2):132–7
-
(2013)
Basic Clin Pharmacol Toxicol.
, vol.112
, Issue.2
, pp. 132-137
-
-
Ancrenaz, V.1
Deglon, J.2
Samer, C.3
Staub, C.4
Dayer, P.5
Daali, Y.6
-
23
-
-
85020888323
-
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study
-
PID: 28065907
-
Hauguel-Moreau M, Boccara F, Boyd A, Salem JE, Brugier D, Curjol A, et al. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. Eur Heart J. 2017;38(21):1676–86
-
(2017)
Eur Heart J.
, vol.38
, Issue.21
, pp. 1676-1686
-
-
Hauguel-Moreau, M.1
Boccara, F.2
Boyd, A.3
Salem, J.E.4
Brugier, D.5
Curjol, A.6
-
24
-
-
77952584975
-
A phenotype–genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir
-
PID: 20147896
-
Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, et al. A phenotype–genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010;87(6):735–42
-
(2010)
Clin Pharmacol Ther.
, vol.87
, Issue.6
, pp. 735-742
-
-
Dumond, J.B.1
Vourvahis, M.2
Rezk, N.L.3
Patterson, K.B.4
Tien, H.C.5
White, N.6
-
25
-
-
84877920349
-
Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A
-
PID: 23589366
-
Fukushima K, Kobuchi S, Mizuhara K, Aoyama H, Takada K, Sugioka N. Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A. J Pharm Sci. 2013;102(6):2044–55
-
(2013)
J Pharm Sci.
, vol.102
, Issue.6
, pp. 2044-2055
-
-
Fukushima, K.1
Kobuchi, S.2
Mizuhara, K.3
Aoyama, H.4
Takada, K.5
Sugioka, N.6
-
26
-
-
18444373524
-
Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats
-
PID: 15635177
-
Kageyama M, Namiki H, Fukushima H, Terasaka S, Togawa T, Tanaka A, et al. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull. 2005;28(1):130–7
-
(2005)
Biol Pharm Bull.
, vol.28
, Issue.1
, pp. 130-137
-
-
Kageyama, M.1
Namiki, H.2
Fukushima, H.3
Terasaka, S.4
Togawa, T.5
Tanaka, A.6
-
27
-
-
1542314451
-
Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats
-
PID: 14985144
-
Perloff MD, von Moltke LL, Greenblatt DJ. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica. 2004;34(2):133–50
-
(2004)
Xenobiotica.
, vol.34
, Issue.2
, pp. 133-150
-
-
Perloff, M.D.1
von Moltke, L.L.2
Greenblatt, D.J.3
-
28
-
-
77958605375
-
Dose-related reduction in bupropion plasma concentrations by ritonavir
-
PID: 20484617
-
Park J, Vousden M, Brittain C, McConn DJ, Iavarone L, Ascher J, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol. 2010;50(10):1180–7
-
(2010)
J Clin Pharmacol.
, vol.50
, Issue.10
, pp. 1180-1187
-
-
Park, J.1
Vousden, M.2
Brittain, C.3
McConn, D.J.4
Iavarone, L.5
Ascher, J.6
-
29
-
-
84879837326
-
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial
-
PID: 23441978
-
Kakuda TN, DeMasi R, van Delft Y, Mohammed P. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med. 2013;14(7):421–9
-
(2013)
HIV Med.
, vol.14
, Issue.7
, pp. 421-429
-
-
Kakuda, T.N.1
DeMasi, R.2
van Delft, Y.3
Mohammed, P.4
-
30
-
-
34247256797
-
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
-
PID: 17361128
-
Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735–41
-
(2007)
Clin Pharmacol Ther.
, vol.81
, Issue.5
, pp. 735-741
-
-
Farid, N.A.1
Payne, C.D.2
Small, D.S.3
Winters, K.J.4
Ernest, C.S.5
Brandt, J.T.6
-
31
-
-
84861820192
-
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy
-
PID: 21628601
-
Riesmeyer JS, Salazar DE, Weerakkody GJ, Ni L, Wrishko RE, Ernest CS 2nd, et al. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol. 2012;52(6):789–97
-
(2012)
J Clin Pharmacol.
, vol.52
, Issue.6
, pp. 789-797
-
-
Riesmeyer, J.S.1
Salazar, D.E.2
Weerakkody, G.J.3
Ni, L.4
Wrishko, R.E.5
Ernest, C.S.6
-
32
-
-
84882435513
-
-
Parsippany, NJ: Daiichi Sankyo, Inc. and Eli Lilly and Company, Accessed May 2017
-
Efient: product information. Parsippany, NJ: Daiichi Sankyo, Inc. and Eli Lilly and Company. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000984/WC500021971.pdf. Accessed May 2017
-
(2009)
Efient: Product Information
-
-
-
33
-
-
84868332790
-
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy
-
PID: 23117779
-
Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012;308(17):1785–94
-
(2012)
JAMA.
, vol.308
, Issue.17
, pp. 1785-1794
-
-
Gurbel, P.A.1
Erlinge, D.2
Ohman, E.M.3
Neely, B.4
Neely, M.5
Goodman, S.G.6
-
34
-
-
85020881424
-
HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm
-
PID: 28087604
-
Gurbel PA, deFilippi CR, Bliden KP, Tantry US. HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm. Eur Heart J. 2017;38(21):1687–9
-
(2017)
Eur Heart J.
, vol.38
, Issue.21
, pp. 1687-1689
-
-
Gurbel, P.A.1
deFilippi, C.R.2
Bliden, K.P.3
Tantry, U.S.4
-
35
-
-
84988925087
-
Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach
-
PID: 27264793
-
Marsousi N, Samer CF, Fontana P, Reny JL, Rudaz S, Desmeules JA, et al. Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin Pharmacol Ther. 2016;100(3):295–304
-
(2016)
Clin Pharmacol Ther.
, vol.100
, Issue.3
, pp. 295-304
-
-
Marsousi, N.1
Samer, C.F.2
Fontana, P.3
Reny, J.L.4
Rudaz, S.5
Desmeules, J.A.6
|